We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
China’s medical products regulator has approved clinical trials for a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group, the Chinese company said late on Tuesday.